Modality
ERT
MOA
PLK4i
Target
GPRC5D
Pathway
Angiogenesis
HNSCCSchizophrenia
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
May 2019
→ Dec 2026
Phase 1Current
NCT07553464
1,944 pts·HNSCC
2020-10→2026-12·Active
NCT08216402
489 pts·HNSCC
2019-05→2026-11·Terminated
2,433 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-087mo awayPh2 Data· HNSCC
2026-12-128mo awayPh2 Data· HNSCC
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1/2
Termina…
P1/2
Active
Catalysts
Ph2 Data
2026-11-08 · 7mo away
HNSCC
Ph2 Data
2026-12-12 · 8mo away
HNSCC
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07553464 | Phase 1/2 | HNSCC | Active | 1944 | CfB |
| NCT08216402 | Phase 1/2 | HNSCC | Terminated | 489 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| ASN-7408 | Ascendis Pharma | NDA/BLA | GPRC5D |